We are using the incredible regenerative mechanisms of the body to tackle different health issues. We are starting with the development of a unique solution to combat hair loss, which works by re-activating dormant hair follicle stem cells in order to promote hair growth and prevent hair loss in sufferers of common hair loss. The potential of stem cell driven regeneration is beyond comprehension – we are starting by combating hair loss, but can quickly apply our mechanisms to wound healing and dental gum regeneration. There are some truly staggering opportunities for the application of this technology to adjacent markets; we ultimately plan to become a multi-division company which leverages our scientific knowledge to help a vast number of people around the world.

Technology field

Mane Biotech is a regenerative medicine company, leveraging the founders’ combined research experience of over 24 years in Cell Biology and Electronic Engineering in order to develop a medical device hardware solution to combat hair loss.

Technology and USP

We are developing a lightweight, wearable smart device which senses the user’s hair coverage/scalp condition in order to provide personalised stimuli, reactivating the user’s hair follicle stem cells to combat common hair loss. Our pioneering, patent pending technology presents an effective, safe, affordable and side effect-less solution to hair loss sufferers, who have been let down by the same ineffective or expensive hair loss treatments for decades. Additionally, our device represents the very first tailored hair loss solution available over the counter.

Development until now

We have proven the scientific principle behind our treatment at a cellular level, and are now working with the leading hair and skin research organisation, Monasterium Laboratory, in order to optimise our stimuli on hair follicle biopsies. We have also built an initial beta prototype in order to develop user experience, with an improved device currently under development in collaboration with local design companies in Cologne.

Capital requirements:

In August 2019 we raised pre-seed funding from the prestigious deep tech investor, Entrepreneur First. We are now looking to raise €200k in order to develop our next generation of prototype device, in addition to carrying out further volunteer trials to optimise the efficacy of our device stimuli in users. Following this funding round, we would look to raise a seed round of approximately €2M in Q3/4 2020 in order to develop our market ready device, obtain medical device regulation and begin our Go To Market strategy.